Friday, September 30, 2016 11:17:37 AM
Ref June 30 2016 10K: http://www.otcmarkets.com/financialReportViewer?symbol=ERBB&id=160795
At June 30, 2016, 7,247,693,042 common shares issued and outstanding
June 30, 2016 LIABILITIES
CURRENT
Loans from shareholders $1,992,818
Debentures payable and accrued interest $6,169,406
$6,169,406 + $1,992,818 = $8,162,224
The debentures accrue interest at 10% per annum and will convert into the company’s common stock at 50% of the lowest closing bid price 12 months before the conversion date.
Lowest closing bid price in past 12 months = .0005 - 50% = .00025
$8,162,224 / .00025 = 32,648,896,000
32,648,896,000 + 7,247,693,042 = 39,896,589,042 (3.8 billion) Fully diluted outstanding
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM